Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | UBE2N | P61088 | 1/20 | 0.45 |
| ▸ | HTR6 | P50406 | 8/20 | 0.45 |
| ▸ | KLK7 | P49862 | 4/20 | 0.41 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.40 |
| ▸ | BRD4 | O60885 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | ALDH3A1 | P30838 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | NOD1 | Q9Y239 | 1/20 | 0.39 |
| ▸ | PIM1 | P11309 | 1/20 | 0.39 |
| ▸ | PIM2 | Q9P1W9 | 1/20 | 0.39 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.38 |
| ▸ | RAPGEF4 | Q8WZA2 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9904381 | 0.92 | L3MBTL1 (0.43) | L3MBTL1KDM4EUBE2NHTR6KLK7 | |
| SCHEMBL9942502 | 0.86 | L3MBTL1 (0.47) | L3MBTL1KDM4EUBE2NHTR6KLK7 | |
| SCHEMBL9904636 | 0.86 | L3MBTL1 (0.50) | L3MBTL1KDM4EUBE2NHTR6KLK7 | |
| SCHEMBL31315847 | 0.83 | KLK7 (0.48) | L3MBTL1KDM4EUBE2NHTR6KLK7 | |
| SCHEMBL31315843 | 0.82 | KDM4E (0.52) | L3MBTL1KDM4EUBE2NHTR6KLK7 | |
| SCHEMBL31593168 | 0.82 | KDM4E (0.52) | L3MBTL1KDM4EUBE2NHTR6KLK7 | |
| SCHEMBL9904700 | 0.79 | L3MBTL1 (0.41) | L3MBTL1KDM4EUBE2NHTR6KLK7 | |
| SCHEMBL19611706 | 0.78 | HTR6 (0.49) | L3MBTL1KDM4EUBE2NHTR6KLK7 | |
| SCHEMBL31315863 | 0.78 | KDM1A (0.50) | L3MBTL1KDM4EUBE2NHTR6KLK7 | |
| SCHEMBL9904294 | 0.77 | L3MBTL1 (0.40) | L3MBTL1KDM4EUBE2NHTR6KLK7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9090593-B2 | Bicyclic compounds as Pim inhibitors | AMGEN INC. (US) | 2015-07-28 | — | — | US | disclosed |
| US-9090593-B2 | Bicyclic compounds as Pim inhibitors | AMGEN INC. (US) | 2015-07-28 | — | — | US | disclosed |
| US-9090593-B2 | Bicyclic compounds as Pim inhibitors | AMGEN INC. (US) | 2015-07-28 | — | — | US | disclosed |
| EP-2796456-A1 | Bicyclic compounds as Pim inhibitors | Amgen Inc. (US) | 2014-10-29 | — | — | EP | disclosed |
| EP-2796456-A1 | Bicyclic compounds as Pim inhibitors | Amgen Inc. (US) | 2014-10-29 | — | — | EP | disclosed |
| US-20140031360-A1 | BICYCLIC COMPOUNDS AS PIM INHIBITORS | AMGEN INC. (US) | 2014-01-30 | — | — | US | disclosed |
| US-20140031360-A1 | BICYCLIC COMPOUNDS AS PIM INHIBITORS | AMGEN INC. (US) | 2014-01-30 | — | — | US | disclosed |
| US-20140031360-A1 | BICYCLIC COMPOUNDS AS PIM INHIBITORS | AMGEN INC. (US) | 2014-01-30 | — | — | US | disclosed |
| EP-2649065-A1 | BICYCLIC COMPOUNDS AS PIM INHIBITORS | Amgen Inc. (US) | 2013-10-16 | — | — | EP | disclosed |
| WO-2012078777-A1 | BICYCLIC COMPOUNDS AS PIM INHIBITORS | AMGEN INC. (US) | 2012-06-14 | — | — | WO | disclosed |
| WO-2012078777-A1 | BICYCLIC COMPOUNDS AS PIM INHIBITORS | AMGEN INC. (US) | 2012-06-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140031360-A1 | BICYCLIC COMPOUNDS AS PIM INHIBITORS | PIM1, PIM2, PIM3 | L3MBTL1 1581/4885KDM4E 539/4885UBE2N 2697/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.